Does Medicare Cover Ozempic, Wegovy & Zepbound? The 2026 GLP-1 Bridge, Explained

It's the question our team hears more than almost any other right now: "Will Medicare pay for my Ozempic?" — or Wegovy, or Zepbound, or the new weight-loss pills so many people are asking about. The honest answer has always depended on why the drug is prescribed. But as of July 1, 2026, that answer changed in a major way. For the first time ever, there's a program that lets some people on Medicare get these medications for weight loss. Here is the full picture, in plain English.

The quick answer

Standard Medicare drug plans cover GLP-1 medications only when they're prescribed for an approved medical condition (such as type 2 diabetes, heart disease, or sleep apnea) — never for weight loss on its own. A new temporary program called the Medicare GLP-1 Bridge, launched July 1, 2026, now lets eligible members get Wegovy, Zepbound, or Foundayo for weight management at a $50 monthly copay.

First, the rule that's held true for years

GLP-1 drugs — the family that includes Ozempic, Wegovy, Mounjaro, and Zepbound — can cost $1,000 or more a month without coverage. Whether a Medicare drug plan (Part D) pays for them has always come down to one thing: the medical reason on the prescription.

By law, standard Medicare Part D has never been permitted to cover a medication used solely for weight loss. But these same drugs are FDA-approved to treat other conditions, and when they're prescribed for one of those, a drug plan can cover them like any other medication. That's why the same box of medicine might be covered for one person and denied for another — the difference is the diagnosis behind it.

When Medicare covers each drug (the medical-condition path)

Here's how the most common GLP-1 medications line up under a standard 2026 Part D plan. Coverage always depends on the specific plan's formulary and rules, but this is the general picture:

Drug	Covered by Part D when prescribed for…	Not covered for
Ozempic	Type 2 diabetes	Weight loss
Mounjaro	Type 2 diabetes	Weight loss
Wegovy	Reducing heart-attack / stroke risk in people with heart disease and obesity	Weight loss alone
Zepbound	Moderate-to-severe obstructive sleep apnea in adults with obesity	Weight loss alone

 

Notice the pattern: Ozempic and Mounjaro are diabetes drugs, so Medicare covers them for diabetes. Wegovy and Zepbound are the “weight” versions of the same medicines, but the FDA has also approved them for specific medical problems — heart-attack prevention and sleep apnea — and Medicare can cover them for those uses. What Medicare would not touch, until now, was a prescription written simply “for weight loss.”

A real-world example

Two neighbors both take Zepbound. One was prescribed it for obstructive sleep apnea, so her Part D plan covers it. The other simply wants to lose weight, so his plan said no — until the new Bridge program opened a door for him. Same drug, two very different answers.

The big change: the Medicare GLP-1 Bridge (started July 1, 2026)

On July 1, 2026, Medicare launched a temporary program called the Medicare GLP-1 Bridge. For the first time, it lets eligible people on Medicare get certain GLP-1 drugs specifically for weight management — the exact use that was off-limits before — for a flat $50 copay per month.

It's called a "bridge" because it's a stopgap while Medicare studies how to handle these drugs long term. It runs through December 31, 2027. Three things make it unusual, and worth understanding:

1. Only three drugs, at $50 a month. The Bridge covers Wegovy (injection or tablet), Zepbound (the KwikPen version), and Foundayo (a newer GLP-1 pill). Each is $50 for a 30-day supply. Note that Ozempic is not on the list.
2. You have to medically qualify. This is not open to anyone who wants to lose a few pounds. You must be enrolled in a Medicare drug plan and meet weight-and-health criteria, and a doctor must submit a prior-authorization request to Medicare's central processor before the pharmacy can release the drug.
3. The $50 sits outside your regular drug plan. Because the Bridge is a separate federal program, those $50 copays do not count toward your Part D deductible or your $2,100 annual out-of-pocket cap — and Extra Help (the low-income subsidy) can't be applied to these Bridge drugs.

Who qualifies for the $50 Bridge copay?

You first need to be enrolled in a Medicare drug plan — either a standalone Part D plan or a Medicare Advantage plan that includes drug coverage. From there, you must meet one of these weight-and-health thresholds (BMI is a standard height-to-weight number a doctor can calculate in seconds):

• BMI of 35 or higher — no other condition required.
• BMI of 30 or higher plus heart failure, uncontrolled high blood pressure, or chronic kidney disease.
• BMI of 27 or higher plus prediabetes, a prior heart attack or stroke, or peripheral artery disease.

The medication also has to be prescribed for chronic weight management — not for diabetes. (For people who have diabetes, a GLP-1 is likely covered the normal Part D way instead.)

How to actually get it

The Bridge doesn't work like a normal trip to the pharmacy. The paperwork runs through Medicare, not just the drug plan:

4. Talk with the doctor. Confirm the criteria are met and that a covered Bridge drug is appropriate.
5. The doctor submits the request. They send a prior authorization and the prescription to Medicare's central processor, which verifies eligibility.
6. Pick it up for $50. Once it's approved, the processor pays the claim and the pharmacy releases the medication for the $50 copay.

Official details and an eligibility check are available at Medicare.gov/glp1bridge.

Don't stop a prescription that's already working

If a GLP-1 like Ozempic, Mounjaro, Wegovy, or Zepbound is already covered for diabetes, heart disease, or sleep apnea, keep it as-is — that path may cost less, and it counts toward the $2,100 out-of-pocket cap. The Bridge is designed for people who couldn't get coverage before because the prescription was for weight loss.

What this means for you

For anyone who has been paying full price for a weight-loss GLP-1 — or going without because the sticker price was impossible — the Bridge could bring a $1,000-plus monthly cost down to $50. That's a meaningful change for a lot of people living on a fixed income.

Two cautions are worth keeping in mind. First, the Bridge is temporary (through the end of 2027), so it's wise to talk with a doctor about a long-term plan, not just this window. Second, GLP-1 rules are changing faster than almost anything else in Medicare right now, and every drug plan handles the medical-condition path a little differently. If it isn't clear which lane applies — covered for a condition, eligible for the Bridge, or neither — that's exactly the kind of question worth a short conversation before assuming the worst.

Quick recap

• Standard Part D covers GLP-1 drugs based on the diagnosis: Ozempic and Mounjaro for diabetes, Wegovy for heart-risk reduction, Zepbound for sleep apnea — never for weight loss alone.
• The new Medicare GLP-1 Bridge (July 1, 2026 – Dec 31, 2027) covers Wegovy, Zepbound KwikPen, and Foundayo for weight management at a $50 monthly copay.
• To qualify: a Medicare drug plan, a qualifying BMI (with certain conditions at lower BMIs), and a prior authorization from a doctor. Ozempic is not on the Bridge list.
• The $50 Bridge copay does not count toward the Part D deductible or the $2,100 cap, and Extra Help can't be used for it.
• If a GLP-1 is already covered for a medical condition, that path usually costs less and counts toward the cap — keep it.

Common questions

Does Medicare cover Ozempic?

Medicare Part D covers Ozempic only when it's prescribed for type 2 diabetes, which is what the FDA approved it to treat. Medicare will not cover Ozempic when it's prescribed purely for weight loss, and Ozempic is not one of the drugs available through the new Medicare GLP-1 Bridge program.

Does Medicare cover Wegovy or Zepbound for weight loss?

Historically, no — federal law barred Medicare Part D from covering any drug used only for weight loss. That changed on July 1, 2026 with the Medicare GLP-1 Bridge, which lets eligible Part D members get Wegovy, Zepbound (KwikPen), or Foundayo for chronic weight management at a $50 copay per month. Wegovy and Zepbound may also be covered the standard way when prescribed for a covered medical condition such as heart disease or sleep apnea.

What is the Medicare GLP-1 Bridge program?

It's a temporary federal demonstration that runs from July 1, 2026 through December 31, 2027. It lets eligible Medicare Part D members fill Wegovy, Zepbound (KwikPen), or Foundayo for chronic weight management at a $50 copay for each 30-day supply, even though standard Part D still can't cover those drugs for weight loss alone.

Who qualifies for the $50 GLP-1 Bridge copay?

You must be enrolled in a Medicare drug plan and meet one of the weight-related criteria: a BMI of 35 or higher; a BMI of 30 or higher with heart failure, uncontrolled high blood pressure, or chronic kidney disease; or a BMI of 27 or higher with prediabetes, a prior heart attack or stroke, or peripheral artery disease. A doctor also has to submit a prior authorization to Medicare's central processor.

Does the $50 copay count toward my $2,100 drug cap?

No. Because the Bridge is a separate program from your regular drug plan, the $50 copay does not count toward your Part D deductible or the $2,100 annual out-of-pocket cap, and Extra Help (the low-income subsidy) can't be applied to these Bridge drugs.

Not sure whether your GLP-1 is covered?

Our licensed agents can check whether your medication is covered under your current plan, or whether the Bridge is a fit — free, and with no pressure.